S2.1 Enzyme replacement therapy (ERT) in Glycogen Storage Disease Type II: the first treatment developed
نویسندگان
چکیده
Since 2006 ERT is available in Europe and numerous studies were reported both in infantile and in juvenile adult patients that demonstrated variable efficacy (1, 2). We have followed infants treated with ERT either early in the first year or later. In one child with onset at birth, diagnosed in the third day of life we observed an excellent long-term clinical response on severe bradycardia and reduction of left ventricular mass index in cardiomyopathy (3) while in another child where the therapy was post-pond no such response was observed: in this second case a large connective tissue replacement was present in the biopsy after ERT. In juvenile and late onset cases a large experience was collected by the Italian group of GSDII (4) and will be soon reported in full. Beside the clinical follow-up we also did a repeated second biopsy after ERT in two cases after 6 months in a 17 year old juvenile case and after 36 months of ERT in a 63 year ventilator dependent woman and we observed less degree of vacuolization in muscle fibers. We documented that ERT improves muscle fiber trophism and decreases PAS positivity, as well as the extensive muscle autophagic vacuolization. We did observe that ERT is effective in both infantile and late-onset GSDII cases, but at a different extent. To explain the difference of ERT in late onset cases we suppose that fiber sarcolemmal membrane compartimentalization around autophagosomes might contribute to the different response in infants and adults; in fact we previously reported (5) that there is a greater degree of fiber sarcolemmal membranes around vacuoles in muscle fibers of late-onset GSDII, versus classical infantile Pompe patients. This protective mechanism may influence the delivery of ERT in adult cases. Furthermore a high antibody titer against recombinant enzyme has been observed (1, 6) both in infants and in adults and might influence ERT efficacy. Finally body composition (I.e fat and connective tissue) and the different mannose receptor density in various tissues (heart, skeletal muscle, diaphragm) has to be considered. ERT is the first treatment developed for GSDII, but it needs further refinements. Several trials are in fact exploring new avenues of treatment (chaperons, new compounds with different affinity for mannose receptor, immunotherapy, etc.).
منابع مشابه
A New Mutation Causing Severe Infantile-Onset Pompe Disease Responsive to Enzyme Replacement Therapy
Pompe disease (PD), also known as “glycogen storage disease type II (OMIM # 232300)” is a rare autosomal recessive disorder characterized by progressive glycogen accumulation in cellular lysosomes. It ultimately leads to cellular damage. Infantile-onset Pompe disease (IOPD) is the most severe type of this disease and is characterized by severe hypertrophic cardiomyopathy and generalized hypoton...
متن کاملTherapeutic approaches in Glycogen Storage Disease type II (GSDII)/Pompe disease
Glycogen storage disease type II (GSDII)/Pompe disease is an autosomal recessive multi-system disorder due to a deficiency of the glycogen-degrading lysosomal enzyme, acid alpha-glucosidase (GAA). Without adequate levels of GAA, there is a progressive accumulation of glycogen inside the lysosome, resulting in lysosomal expansion in many tissues, although the major clinical manifestations are se...
متن کاملEvaluation of muscle biopsy in late-onset GSDII patients before and after enzyme replacement therapy (ERT)
Introduction Glycogen storage disease, glycogenosis type II (GSDII), or Pompe disease (OMIM 23230), is an autosomal recessive lysosomal storage disorder that results from a deficiency in the acid alpha glucosidase (GAA) enzyme. The disease is characterized by progressive accumulation of lysosomal glycogen in various tissues, primarily in cardiac and skeletal muscles. The histopathological hallm...
متن کاملPompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy.
Pompe disease (glycogen storage disease type II, acid maltase deficiency) is a progressive metabolic myopathy caused by deficiency of the lysosomal enzyme acid alpha-glucosidase. This leads to an accumulation of glycogen in various tissues of the body, most notably in skeletal muscle. The disease has an autosomal recessive inheritance with a predicted frequency of 1 :40.000. Pompe disease is a ...
متن کاملDivergent clinical outcomes of alpha-glucosidase enzyme replacement therapy in two siblings with infantile-onset Pompe disease treated in the symptomatic or pre-symptomatic state
Pompe disease is an autosomal recessive, lysosomal glycogen storage disease caused by acid α-glucosidase deficiency. Infantile-onset Pompe disease (IOPD) is the most severe form and is characterized by cardiomyopathy, respiratory distress, hepatomegaly, and skeletal muscle weakness. Untreated, IOPD generally results in death within the first year of life. Enzyme replacement therapy (ERT) with r...
متن کاملHyaluronidase increases the biodistribution of acid alpha-1,4 glucosidase in the muscle of Pompe disease mice: an approach to enhance the efficacy of enzyme replacement therapy.
Pompe disease (glycogen storage disease type II) is a glycogen storage disease caused by a deficiency of the lysosomal enzyme, acid maltase/acid alpha-1,4 glucosidase (GAA). Deficiency of the enzyme leads primarily to intra-lysosomal glycogen accumulation, primarily in cardiac and skeletal muscles, due to the inability of converting glycogen into glucose. Enzyme replacement therapy (ERT) has be...
متن کامل